SCHEDULE: Pau Hung To Discloses 12.75% Stake in Advanced Biomed Inc.

Pau Hung To has reported beneficial ownership of 176,225 shares, representing 12.75% of Advanced Biomed Inc.'s common stock, following a debt-for-equity exchange and subsequent stock splits.

Summary

• Pau Hung To has filed a Schedule 13G, indicating a passive ownership stake in Advanced Biomed Inc.
• The reporting person beneficially owns 176,225 shares of common stock.
• This ownership represents 12.75% of the class of securities.
• The shares were acquired on October 24, 2022, through a Debt-For-Equity Exchange Agreement dated June 30, 2022, to satisfy indebtedness owed by the issuer.
• The reported share count has been adjusted for subsequent stock splits: a 4-for-1 forward split on May 16, 2023, a 1-for-5 reverse split on October 15, 2024, and a 1-for-20 reverse split on February 20, 2026.
• The percentage ownership is based on 1,382,133 shares outstanding as of March 31, 2026, as reported in the Issuer's Form 10-Q filed on May 15, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the nature of a Schedule 13G indicating a passive stake, with no new strategic information or positive operational updates provided.

Positives

• The reporting person has a significant passive stake (12.75%) in Advanced Biomed Inc., which could indicate confidence in the company's long-term prospects.
• The shares were acquired through a debt-for-equity conversion, suggesting a resolution of past financial obligations between the reporting person and the issuer.

Negatives

• The filing is a Schedule 13G, which typically signifies a passive investment without intent to influence control, offering no immediate strategic positive implications for the company's operations.
• The significant number of reverse stock splits mentioned (1-for-5 and 1-for-20) could indicate past financial difficulties or a strategy to maintain stock price levels, which might be viewed negatively by some investors.

Risks

• The filing does not explicitly mention any new risks, but the nature of a Schedule 13G implies the reporting person is not actively involved in management or strategic direction, leaving operational risks solely to the company's management.
• The historical stock splits could suggest underlying financial challenges or a need to meet listing requirements, which may pose a risk to future share performance if not managed effectively.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors or individuals who acquire a significant stake in a company but do not intend to influence its control. This filing indicates a passive investment by Pau Hung To in Advanced Biomed Inc., a biotechnology company, without providing operational or strategic insights into the company's performance.

Related Party Transactions

• The acquisition of shares by Pau Hung To was through a Debt-For-Equity Exchange Agreement dated June 30, 2022, to satisfy indebtedness owed by the Issuer to the Reporting Person. This is a related party transaction as it involves the settlement of debt between the reporting person and the issuer.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive ownership stake, which may be viewed neutrally or positively if the investor is seen as long-term supportive, but it does not signal any immediate change in corporate strategy or value.
• Creditors: The debt-for-equity exchange implies that some debt owed by Advanced Biomed Inc. to Pau Hung To has been converted into equity, potentially reducing the company's immediate debt burden.
• Management: The Schedule 13G filing indicates no intent to influence control, suggesting management's current operational and strategic authority remains unchanged.

Next Steps

• The reporting person will continue to hold shares as disclosed.
• Advanced Biomed Inc. will continue its operations as per its business strategy, with no direct influence from this filing on its immediate next steps.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Debt-For-Equity Exchange, Stock Splits, Passive Investment, Advanced Biomed Inc.